Results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate targeting cancer stem cells (CSCs) have been released. The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials are now open in combinations with standard therapy for pancreatic, ovarian and liver cancers.
News Source
News Source
No comments:
Post a Comment